Treats venous thrombosis and its extension, pulmonary embolism (PE). ANDA 90935, held by Invagen Pharms. Warfarin Sodium.
As of Nov 16, 2026, ANDA 90935 (Warfarin Sodium), held by Invagen Pharms, was first approved by FDA on May 25, 2011, with 4 approved supplements and 0 published complete response letters.
1. INDICATIONS AND USAGE Warfarin sodium tablets are indicated for: Prophylaxis and treatment of venous thrombosis and its extension, pulmonary embolism (PE). Prophylaxis and treatment of thromboembolic complications associated with atrial fibrillation (AF) and/or cardiac valve replacement. Reduction in the risk of death, recurrent myocardial infarction (MI), and thromboembolic events such as stroke or systemic embolization after myocardial infarction Limitations of Use Warfarin sodium tablets have no direct effect on an established thrombus, nor does it reverse ischemic tissue damage.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 25, 2011 | Original application | Approved | None posted |
| Warfarin Sodium1MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium2MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium2.5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium3MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium4MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium6MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium7.5MG · tablet;oral | Warfarin Sodium | Rx |
| Warfarin Sodium10MG · tablet;oral | Warfarin Sodium | Rx |
| Sep 26, 2019 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 26, 2019 | Supplement 5Labeling · Standard review | Approved | None posted |
| Sep 26, 2019 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 13, 2013 | Supplement 1Labeling · Standard review | Approved | None posted |
| May 25, 2011 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters